CVS Health (CVS) Tops Q2 EPS by 36c, Raises FY EPS Guidance

CVS Health (NYSE: CVS) reported Q2 EPS of $2.42, $0.36 better than the analyst estimate of $2.06. Revenue for the quarter came in at $72.6 billion versus the consensus estimate of $70.11 billion.

GUIDANCE:

CVS Health sees FY2021 EPS of $7.70-$7.80, versus the consensus of $7.66.

• The Company raised its full year 2021 GAAP diluted EPS guidance range to $6.35 to $6.45 from $6.24 to $6.36 and its full year 2021 Adjusted EPS guidance range to $7.70 to $7.80 from $7.56 to $7.68 and raised its full year 2021 cash flow from operations guidance range to $12.5 billion to $13.0 billion from $12.0 billion to $12.5 billion.

For earnings history and earnings-related data on CVS Health (CVS) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• CVS Pharmacy® expands GLP‑1 support to lower costs, improve access, and help patients stay on therapy
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings